ASCO 2012 Report – Trametinib delays tumour growth and extends survival in certain melanoma patients
by Marybeth Burke – Median progression-free survival (PFS) was significantly greater in the trametinib group, 4.8 months, vs the chemotherapy group, 1.4 months, according to a study presented